Arrowstreet Capital Limited Partnership Has $3.49 Million Stock Holdings in MiMedx Group, Inc. (NASDAQ:MDXG)

Arrowstreet Capital Limited Partnership increased its position in shares of MiMedx Group, Inc. (NASDAQ:MDXG) by 484.2% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 362,481 shares of the company’s stock after buying an additional 300,433 shares during the quarter. Arrowstreet Capital Limited Partnership owned about 0.25% of MiMedx Group worth $3,487,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Disciplined Growth Investors Inc. MN increased its holdings in shares of MiMedx Group by 0.8% during the third quarter. Disciplined Growth Investors Inc. MN now owns 355,387 shares of the company’s stock valued at $2,100,000 after acquiring an additional 2,737 shares in the last quarter. IMG Wealth Management Inc. bought a new position in shares of MiMedx Group in the 4th quarter worth $28,000. SkyView Investment Advisors LLC grew its position in MiMedx Group by 30.0% in the 3rd quarter. SkyView Investment Advisors LLC now owns 13,000 shares of the company’s stock valued at $77,000 after purchasing an additional 3,000 shares during the period. Principal Financial Group Inc. increased its stake in MiMedx Group by 6.3% during the 3rd quarter. Principal Financial Group Inc. now owns 55,495 shares of the company’s stock valued at $328,000 after purchasing an additional 3,292 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its holdings in MiMedx Group by 0.7% during the fourth quarter. Bank of New York Mellon Corp now owns 504,007 shares of the company’s stock worth $4,849,000 after buying an additional 3,300 shares during the last quarter. 79.15% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, insider Kimberly Maersk-Moller sold 4,106 shares of the stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $7.89, for a total transaction of $32,396.34. Following the completion of the transaction, the insider now directly owns 310,836 shares of the company’s stock, valued at $2,452,496.04. This represents a 1.30 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO William Frank Iv Hulse sold 54,596 shares of the firm’s stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $7.89, for a total transaction of $430,762.44. Following the sale, the chief accounting officer now owns 440,178 shares of the company’s stock, valued at approximately $3,473,004.42. The trade was a 11.03 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 144,018 shares of company stock valued at $1,130,312 over the last three months. Corporate insiders own 1.30% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on MDXG shares. StockNews.com upgraded shares of MiMedx Group from a “buy” rating to a “strong-buy” rating in a report on Friday, April 4th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $13.00 price target on shares of MiMedx Group in a research report on Thursday, February 27th.

MiMedx Group Stock Performance

NASDAQ MDXG opened at $6.86 on Wednesday. The company has a fifty day moving average price of $7.99 and a 200-day moving average price of $7.97. The firm has a market cap of $1.01 billion, a price-to-earnings ratio of 12.47 and a beta of 1.74. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.10 and a quick ratio of 3.53. MiMedx Group, Inc. has a 1 year low of $5.47 and a 1 year high of $10.14.

MiMedx Group (NASDAQ:MDXG) last released its quarterly earnings results on Wednesday, February 26th. The company reported $0.07 earnings per share for the quarter, hitting the consensus estimate of $0.07. The business had revenue of $92.91 million for the quarter, compared to analysts’ expectations of $89.42 million. MiMedx Group had a net margin of 23.86% and a return on equity of 26.21%. As a group, equities research analysts predict that MiMedx Group, Inc. will post 0.3 EPS for the current fiscal year.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.